ArticlePloS one2025
Glucose-containing vs. glucose-free dialysate for patients with maintenance hemodialysis: Study protocol for a multicenter randomized controlled study-GLUMO study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo mitigate the risk of infection and disordered blood lipid metabolism, glucose-free dialysate is widely utilized in China and European countries. While glucose-free dialysis does not necessarily lead to hypoglycemia, several other metabolic adjustments must occur to maintain normal blood glucose levels. Additionally, glucose-free dialysis may also increase the loss of amino acids and the susceptibility to hypotension and cardiovascular events. Incorporating an appropriate amount of glucose into the dialysate can help to offset the insufficient blood glucose during hemodialysis (HD), potentially reducing the incidence of hypoglycemia. Currently, the efficacy and safety of glucose-containing dialysate during HD remain contentious, and this study will be conducted to evaluate the efficacy and safety of 5.5 mmol/L glucose-containing dialysate for maintenance HD patients. STUDY DESIGN AND
methodsA multicenter, prospective, open-label, parallel-group, randomized controlled trial (RCT) will be conducted at more than 30 dialysis centers in China. Approximately 600 participants undergoing maintenance HD will be enrolled. Eligible patients will be randomly assigned to two groups, receiving either glucose-containing dialysate or glucose-free dialysate for HD at a 1:1 ratio, determined by a central computer-generated randomized sequence. The primary outcome is the incidence of the major cardiovascular and cerebrovascular adverse events (MACCE). Secondary outcomes are all-cause mortality, incidence of intradialytic hypotension (IDH), incidence of hypoglycemia, blood pressure and blood glucose variability, dysfunction of vascular access, cardiac function and fatigue level. Outcome assessors and data analysts will be blinded. All data will be analyzed using either intention-to-treat or per-protocol analysis methods. DISCUSSION: The results of this study will provide evidence on the efficacy and safety of 5.5 mmol/L glucose-containing dialysate for maintenance HD patients, and will provide valuable insights for future dialysate selection and the enhancement of dialysis treatment prescriptions. TRIAL REGISTRATION NUMBER: ChiCTR2400083153.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.